A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine

Cerebral Cortex

Volumn 20, Issue 4, 2010, Pages 798-803

  Van Wageningen, Heidi ^a   Jørgensen, Hugo A ^a,b   Specht, Karsten ^a,b   Hugdahl, Kenneth ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

1H MR spectroscopy; Cognitive control; fMRI; Glutamate and glutamine; Memantine

Indexed keywords

EBIXIA; GLUTAMIC ACID; GLUTAMINE; MEMANTINE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; DIAGNOSTIC AGENT; OXYGEN; TRITIUM;

ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DICHOTIC LISTENING; DIZZINESS; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FATIGUE; FEMALE; HEARING; HUMAN; MALE; NAUSEA; NEUROTRANSMISSION; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TASK PERFORMANCE; ANALYSIS OF VARIANCE; AUDITORY STIMULATION; BLOOD; BRAIN MAPPING; DRUG EFFECT; FRONTAL LOBE; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PSYCHOPHYSICS; SCINTISCANNING;

ACOUSTIC STIMULATION; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BRAIN MAPPING; DICHOTIC LISTENING TESTS; FEMALE; FRONTAL LOBE; GLUTAMIC ACID; GLUTAMINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PSYCHOACOUSTICS; TRITIUM; YOUNG ADULT;

EID: 77949363852     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhp145     Document Type: Article

References (51)

1. Andersson M, Reinvang I, Wehling E, Hugdahl K, Lundervold AJ. 2008. A dichotic listening study of attention control in older adults. Scand J Psychol. 49(4):299-304.
2. Areosa SA, Sherriff F, McShane R. 2005. Memantine for dementia. Cochrane Database Syst Rev. 3:CD003154.
3. Asbjørnsen A, Hugdahl K. 1995. Attentional effects in dichotic listening. Brain Lang. 49:189-201.
4. Ashburner J, Friston KJ. 1999. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 7(4):254-266.
5. Beal MF. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 38(3):357-366.
6. Braver TS, Cohen JD. 2000. On the control of control: the role of dopamine in regulating prefrontal function and working memory. In: Monsell S, Driver J, editors. Attention and performance XVIII; control of cognitive processes. Cambridge, MA: MIT Press. p. 713-737.
7. Braver TS, Cohen JD, Barch DM. 2002. The role of prefrontal cortex in normal and disordered cognitive control: a cognitive neuroscience perspective. In: Stuss DT, Knight RT, editors. Principles of frontal lobe function. New York: Oxford University Press. p. 428-447.
8. Cooper JR, Bloom FE, Roth RH. 2002. The biochemical basis of neuropharmacology. 8th ed. Oxford, UK: Oxford University Press.
9. Cull-Candy S, Brickley S, Farrant M. 2001. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 11(3):327-335.
10. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. 2000. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2(2-3):85-97.
11. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. 2008. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 65((2)):154-164.
12. Duncan J, Owen AM. 2000. Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends Neurosci. 23(10):475-483.
13. Fu CH, McGuire PK. 1999. Functional neuroimaging in psychiatry. Philos Trans R Soc Lond B Biol Sci. 354(1387):1359-1370.
14. Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ. 2008. Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry. 32(4):1005-1012.
15. Green MF. 1998. Schizophrenia from a neurocognitive perspective. Boston (MA): Allyn & Bacon.
16. Hall DA, Haggard MP, Akeroyd MA, Palmer AR, Summerfield AQ, Elliott MR, Gurney EM, Bowtell RW. 1999. "Sparse" temporal sampling in auditory fMRI. Hum Brain Mapp. 7(3):213-223.
17. Heinrichs RW. 2000. In search of madness. Schizophrenia and neuroscience. New York: Oxford University Press.
18. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. 2005. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology. 30(12):2275-2282.
19. Hugdahl K, Andersson L. 1986. The "forced-attention paradigm" in dichotic listening to CV-syllables: a comparison between adults and children. Cortex. 22(3):417-432.
20. Hugdahl K, Bodner T, Weiss E, Benke T. 2003. Dichotic listening performance and frontal lobe function. Brain Res Cogn Brain Res. 16(1):58-65.
21. Hugdahl K, Westerhausen R, Alho K, Medvedev S, Laine M, Hamalainen H. 2009. Attention and cognitive control: unfolding the dichotic listening story. Scand J Psychol. 50(1):11-22.
22. Jancke L, Shah NJ. 2002. Does dichotic listening probe temporal lobe functions? Neurology. 58(5):736-743.
23. Korostenskaja M, Nikulin VV, Kicic D, Nikulina AV, Kahkonen S. 2007. Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull. 72(4-6):275-283.
24. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51(3):199-214.
25. Landro NI, Rund BR, Lund A, Sundet K, Mjellem N, Asbjornsen A, Thomsen T, Ersland L, Lundervold A, Smievoll AI, et al. 2001. Honig's model of working memory and brain activation: an fMRI study. Neuroreport. 12(18):4047-4054.
26. Lipton SA. 1993. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16(12):527-532.
27. Lipton SA. 2004. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. 6(Suppl 6):61-74.
28. Loberg EM, Hugdahl K, Green MF. 1999. Hemispheric asymmetry in schizophrenia: a "dual deficits" model. Biol Psychiatry. 45(1):76-81.
29. Magistretti PJ, Pellerin L. 1999. Astrocytes couple synaptic activity to glucose utilization in the brain. News Physiol Sci. 14:177-182.
30. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. 1996. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14(5):301-307.
31. Miller EK, Cohen JD. 2001. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 24:167-202.
32. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 20(2):106-118.
33. Novotny EJ, Jr, Fulbright RK, Pearl PL, Gibson KM, Rothman DL. 2003. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol. 54(Suppl 6):S25-S31.
34. Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 33(6):523-533.
35. Parsons CG, Danysz W, Quack G. 1999. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38(6):735-767.
36. Provencher SW. 1993. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 30(6):672-679.
37. Raczkowski D, Kalat JW, Nebes R. 1974. Reliability and validity of some handedness questionnaire items. Neuropsychologia. 12(1):43-47.
38. Rammsayer TH. 2001. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem. 8(1):20-25.
39. Rossi S. 2006. Australian medicines handbook. Adelaide (Australia): Australian Medicines Handbook Pty Ltd.
40. Rothman DL, Behar KL, Hyder F, Shulman RG. 2003. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol. 65:401-427.
41. Rund BR, Sundet K, Asbjornsen A, Egeland J, Landro NI, Lund A, Roness A, Stordal KI, Hugdahl K. 2006. Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand. 113(4):350-359.
42. Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Loschmann PA. 1997. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett. 224(1):57-60.
43. Schulz H, Jobert M, Coppola R, Herrmann WM, Pantev M. 1996. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology. 33(1):32-40.
44. Stuss DT. 2006. Frontal lobes and attention: processes and networks, fractionation and integration. J Int Neuropsychol Soc. 12(2):261-271.
45. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ. 2003. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 160(12):2231-2233.
46. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, et al. 2002. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 159(11):1944-1946.
47. Thomsen T, Rimol LM, Ersland L, Hugdahl K. 2004. Dichotic listening reveals functional specificity in prefrontal cortex: an fMRI study. Neuroimage. 21(1):211-218.
48. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52(10):829-836.
49. van den Noort M, Specht K, Rimol LM, Ersland L, Hugdahl K. 2007. A new verbal reports fMRI dichotic listening paradigm for studies of hemispheric asymmetry. Neuroimage. 40(2):902-911.
50. van Wageningen H, Jørgensen HA, Specht K, Hugdahl K. 2009. Evidence for glutamatergic neurotransmission in cognitive control in an auditory attention task. Neurosci Lett. 454(3):171-175.
51. Walter B, Blecker C, Kirsch P, Sammer G, Schienle A, Stark R, Vaitl D. 2003. MARINA: an easy to use tool for the creation of MAsks for Region of INterest Analyses. Paper presented at the 9th International Conference of Functional Mapping of the Human Brain. June 19-22. New York. Vol. 19, it is available on CD-Rom in Neuroimage.